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DObjectives:We examined the role of prosthesis–patient mismatch on left ventricular mass regression after aortic
valve replacement for chronic aortic valve regurgitation.
Methods:We selected patients who had complete preoperative and follow-up echocardiograms with measure-
ment of left ventricular mass. Patients were excludedwho hadmoderate or greater aortic valve stenosis, concom-
itant coronary artery bypass grafting, or mitral valve procedures.
Results: Patients’ mean age was 55 17 years; 21% were female. The mean preoperative indexed left ventric-
ular mass was 150  45 g/m2. Patients with mildly (n ¼ 44; mean indexed mass, 126  15 g/m2), moderately
(n¼ 31; mean indexed mass, 168 11 g/m2), or severely (n¼ 15; mean indexed mass, 241 34 g/m2) increased
preoperative indexed left ventricular mass, were similar, except for lower ejection fractions, larger end-diastolic
dimensions, and larger ventricular wall thicknesses in the severely enlarged group (P<.001). Thirteen patients
had prosthesis–patient mismatch and were similar to patients without prosthesis–patient mismatch, except for
a greater body surface area, fewer mechanical valves, and smaller valve sizes in those with prosthesis–patient
mismatch (P<.05). At a mean follow-up of 3.2  2.4 years, the average reduction in indexed left ventricular
mass was 50  38 g/m2; late mass regression was unrelated to labeled valve size, prosthesis–patient mismatch,
or measured indexed effective aortic valve area. A greater preoperative indexed left ventricular mass (P<.001)
was an independent predictor of greater left ventricular mass regression. Despite having greater left ventricular
mass regression, patients with severe preoperative indexed left ventricular mass did not return to normal values
(mean, 142  25 g/m2).
Conclusions: Left ventricular mass regression after aortic valve replacement for chronic aortic regurgitation
is unrelated to indexed prosthetic valve area. Although incomplete, regression is greatest in patients with the
largest preoperative indexed left ventricular mass. (J Thorac Cardiovasc Surg 2011;142:e5-9)Prosthesis–patient mismatch (PPM) is a widely known con-
cept after aortic valve replacement (AVR) in which the ef-
fective orifice area of the prosthetic valve is small in
relation to body size, leaving the patient with residual left
ventricular (LV) outflow obstruction.1 PPM is believed to
be independently associated with mortality after AVR,2-7
although some investigators have not found this to be the
case.8-12 A larger indexed effective orifice area has also
been found to be an independent predictor of greater LV
mass regression in patients with pure aortic stenosis.6 These
studies have focused on patients with aortic stenosis.
It is thought that PPM is an infrequent complication in
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The Journal of Thoracic and C(AR), where the sinus portion of the aorta and the aortic
valve annulus are enlarged, permitting implantation of
larger valve sizes. The objectives of our study were to deter-
mine the degree of LV mass regression in patients who re-
ceived an aortic valve for AR and to identify predictors of
reverse remodeling. Specifically, we were interested in the
influence of PPM on regression of LV hypertrophyMETHODS
After institutional review board approval, we reviewed adult patients
(>18 years) who underwent AVR for AR between January 1, 1996, and Jan-
uary 1, 2006. Patients were excluded if they had moderate or greater aortic
valve stenosis on preoperative transthoracic echocardiography, which was
defined as an aortic valve area of less than 1.5 cm or a qualitative interpre-
tation of moderate aortic valve stenosis. Also excluded were patients with
acute AR owing to aortic dissections or active endocarditis and patients
who had prior or concomitant coronary artery bypass grafting and/or mitral
valve repair or replacement.
Among 301 eligible patients, we reviewed medical records and selected
thosewho had a preoperative and a follow-up transthoracic echocardiogram
available in our echocardiographic database. Echocardiography was per-
formed according to recommendations by the American Society of Echo-
cardiographers.13The echocardiogram must have included measurements
of interventricular septal thickness (SWT), posterior wall thickness
(PWT), and LV end-diastolic dimensions (LVEDD). These measurementsardiovascular Surgery c Volume 142, Number 2 e5
Abbreviations and Acronyms
AR ¼ aortic valve regurgitation
AVR ¼ aortic valve replacement
LV ¼ left ventricular
LVMi ¼ indexed left ventricular mass
PPM ¼ prosthesis–patient mismatch
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Dare required to calculate the LV mass and indexed LV mass (LVMi). The
following formula was used to calculate LVMi:

SWTþPWTþLVEDDÞ3LVEDD3  1:04  0:8þ0:6BSA
where BSAwas body surface area.
Patients were divided into those with and without PPM. Mismatch was
defined as a measured indexed valve area of less than 0.85 cm2/m2 on pre-
dismissal transthoracic echocardiography. Patients were also divided into
terciles of preoperative LVMi: mildly (LVMi< 150 g/m2), moderately
(LVMi 150–200 g/m2), and severely increased (LVMi> 200 g/m2). The
outcome of this study was defined as the change in LVMi at follow-up
from the LVMi recorded before AVR.
Statistical analyses were performed using SAS (version 9.1; SAS Insti-
tute, Inc, Cary, Ind). Data are presented as means and standard deviations or
numbers and percentages, as appropriate. Univariate analyses between
groups were compared using c2 tests or Fisher’s tests for categorical vari-
ables and t tests, 1-way analysis of variance tests, or Kruskal–Wallis tests as
appropriate. Univariate and stepwise multivariate models were created
using linear regression for continuous outcomes and logistic regression
for dichotomous outcomes.
RESULTS
Ninety patients met entry criteria for the study (Table 1).
At operation, the median valve size was 25 mm and 65 pa-
tients (72%) received a bioprosthesis. Thirteen (14%) pa-
tients had PPM. When patients were categorized into
presence or absence of PPM, there were few differences
in preoperative characteristics aside from greater body
surface area in patients who had PPM (2.3 m2 vs 2.0 m2;TABLE 1. Patient demographics
Entire
cohort No PPM PPM
Variable (n ¼ 90) (n ¼ 77) (n ¼ 13) P
Age (y) 54.9  16.7 56.0  16.9 48.9  14.3
Female gender (no.,%) 19 (21.1) 15 (19.5) 4 (30.8)
Hypertension (no.,%) 41 (45.6) 33 (42.9) 8 (61.5)
Sinus rhythm (no.,%) 76 (84.4) 65 (84.4) 11 (84.6)
NYHA class III or IV (no.,%) 41 (45.6) 37 (48.1) 4 (30.8)
BSA (m2) 2.0  0.2 2.0  0.2 2.3  0.3
Mean preoperative EF (%) 56  12 56  12 57  7
Mean preoperative SWT (mm) 11  2 11  2 12  2
Mean preoperative PWT (mm) 11  2 11  2 11  2
Mean preoperative LVEDD (mm) 63  9 64  9 62  8
Mean preoperative LVMi (g/m2) 150  45 161  45 151  46
Continuous variables are expressed as mean  standard deviation. BSA, Body surface are
ventricular mass index; NYHA, New York Heart Association; PPM, prosthesis–patient mi
e6 The Journal of Thoracic and Cardiovascular SurgeP ¼ .002). We then examined differences between patients
divided into terciles of preoperative LVMi: mild (n ¼ 44;
mean LVMi, 126  15 g/m2), moderate (n ¼ 31; mean
LVMi, 168  11 g/m2), or severe (n ¼ 15; mean LVMI,
241  34 g/m2). These groups were similar except for
higher ejection fractions and smaller LV end-diastolic di-
mensions, septal wall thicknesses, and posterior wall thick-
nesses in the mild group (P< .001) (Table 1). Operative
details are given in Table 2.
From predismissal echocardiography, the calculated
mean indexed aortic valve area for the entire cohort was
1.1  0.7 cm2/m2 and the mean gradient across the aortic
valvewas 16 6mmHg. The calculated mean indexed aor-
tic valve area was 0.7 0.1 in patients with PPM and 1.2
0.3 in patients without PPM (P<.001), and the mean gra-
dient across the aortic valve was 24  6 mm Hg in patients
with mismatch and 15  5 mm Hg in patients without mis-
match (P<.001). The mean indexed aortic valve area was
found to be 1.1  0.3 cm2/m2 in the group with mildly
increased LVMi, 1.2  0.4 cm2/m2 in the moderately
increased group, and 1.2 0.2 cm2/m2 in the group with se-
verely enlarged LVMi (P¼ .864). The mean gradient across
the aortic valvewas 17 7mmHg in themild group, 16 6
mm Hg in the moderate group, and 15  5 mm Hg in the
severe group (P ¼ .496).
At amean follow-up of 3.2 2.4 years (median, 2.7; inter-
quartile range, 1.1–5.0 years), LVMi was available in all pa-
tients as specified by the inclusion criteria. No patient had
more than mild prosthetic or periprosthetic regurgitation.
The average reduction in LVMi was 50  38 g/m2. Late LV
mass regression was unrelated to prosthesis type, size, or in-
dexed prosthetic valve area by postoperative echocardiogra-
phy (Table 3, Figure 1). The time to the echocardiogram was
also not predictive ofLVmass reduction (P¼ .055).Agreater
preoperative LVMi (P< .001) was the only independent
predictor of greater LV mass regression. Despite the greatestMildly
increased LVMi
Moderately
increased LVMi
Severely
increased LVMi
value (n ¼ 44) (n ¼ 31) (n ¼ 15) P value
.124 54.9  16.0 55.2  17.2 54.5  18.6 .992
.356 13 (29.5) 5 (16.1) 1 (6.7) .121
.211 20 (45.5) 15 (48.4) 6 (40.0) .267
.932 39 (88.6) 24 (77.4) 14 (93.3) .866
.247 18 (40.9) 15 (48.4) 8 (53.3) .654
.002 2.0  0.2 2.1  0.3 2.0  0.2 .275
.780 60  9 56  11 47  15 <.001
.214 10  2 12  2 13  2 <.001
.456 10  1 11  2 13  2 <.001
.687 59  5 66  8 72  8 <.001
.451 126  15 168  10.8 241  34 <.001
a; EF, ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVMi, left
smatch; PWT, posterior wall thickness; SWT, septal wall thickness.
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TABLE 2. Operative details
Entire
Cohort No PPM PPM
Mild
increased LVMi
Moderate
increased LVMi
Severe
increased LVMi
Variable (n ¼ 90) (n ¼ 77) (n ¼ 13) P value (n ¼ 44) (n ¼ 31) (n ¼ 15) P value
Mean CPB time (min) 86  46 87  46 77  44 .438 91  39 81  58 81  35 .590
Mean crossclamp time (min) 61  32 63  32 51  31 .210 65  32 57  35 58  24 .478
Median labeled valve size (mm) 25 27 25 .019 27 27 25 .224
Mechanical valve (no.,%) 25 (27.8) 25 (32.3) 0 (0.0) .016 12 (27.3) 9 (29.0) 4 (26.7) .981
Aortic root replacement (N,%) 20 (22.2) 19 (24.6) 1 (7.7) .727 12 (27.3) 3 (9.7) 5 (33.3) .263
Ascending aorta replacement (N,%) 3 (3.3) 3 (3.9) 0 (0.0) 2 (4.5) 1 (3.2) 0 (0)
Continuous variables are expressed as mean  standard deviation. CPB, Cardiopulmonary bypass; LVMi, left ventricular mass index; PPM, prosthesis–patient mismatch.
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did not return to normal late LVMi measurements (mean,
142  25 g/m2).
Univariate predictors of return to normal late LVMi (LV
mass < 100 g/m2) included female gender (OR, 3.5;
P ¼ .022), higher preoperative ejection fraction (OR, 1.1
per 1%; P¼ .010), smaller interventricular septal thickness
(OR, 0.8 per 1 mm; P ¼ .028), smaller posterior wall thick-
ness (OR, 0.7 per 1 mm; P¼ .005), smaller LVend-diastolic
dimensions (OR, 0.9 per 1 mm; P ¼.002), smaller LV end-
systolic dimensions (OR, 0.9 per 1 mm; P ¼ .002), and
a smaller preoperative LVMi (OR, 0.9 per 1 g/m2;
P< .001) was predictive of late return to normal LVMi.
The time from the late measurement of LVMi and surgeryTABLE 3. Univariate predictors of LV mass regression after AVR for
chronic AR
Univariate
P value
Clinical variables
Younger age .115
Smaller BSA .092
Male gender .405
Year of operation .408
Absence of hypertension .747
NYHA class .727
Valve size .718
Echocardiographic variables
Larger preoperative SWT <.001
Larger preoperative PWT <.001
Larger preoperative LVEDD <.001
Larger preoperative LVMi <.001
Larger preoperative LVESD .007
Lower preoperative ejection fraction .357
Time between follow-up
echocardiography and operation
.547
Lower postoperative mean aortic valve gradient .583
Smaller postoperative indexed aortic valve area .891
AR, Aortic valve regurgitation; AVR, aortic valve replacement; BSA, body surface
area; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVESD,
left ventricular end-systolic dimension; LVMi, indexed left ventricular mass;
NYHA, New York Heart Association; PWT, posterior wall thickness; SWT, septal
wall thickness.
The Journal of Thoracic and Cdate was not associated with late normal LVMi (P ¼
.928). After adjusting for age and gender, the only indepen-
dent association with late normal LVMi was a smaller
preoperative LVMi (OR, 1.0 per 1 g/m2; P<.001).
Neither the presence of PPM (P ¼ .893) nor the indexed
aortic valve area (P ¼ .887) was predictive of late return to
normal LVMi. Patients with the largest valve sizes (27, 29,
and 31 mm) were more likely to have a late normal LVMi
when compared with the smallest valve size (21 mm)
(OR, 0.2; P ¼.044), but there was no difference between
valve sizes (23 and 25 mm) and the smallest valve size
(21 mm) (OR, 0.2; P ¼ .081).DISCUSSION
In this study, the extent of LVmass regression was not re-
lated to valve type, valve size, indexed effective prosthetic
valve area, prosthetic valve gradient, or PPM. Indeed, the
only significant predictor of extent of LV mass regression
was degree of LVhypertrophy preoperatively.Wewere care-
ful to select patients who had pure aortic valve regurgitation,
and we were careful to exclude concomitant diagnoses that
might independently influence LV mass, such as moderate
or more aortic valve stenosis, greater than moderate mitral
valve regurgitation, and known coronary artery disease.
There are few published data that specifically address the
potential problem of PPM and surgery for AR. PPMwas un-
common (14%) in our patients undergoing AVR for chronic
AR. Our findings are similar to results of Price and associ-
ates,14 who reported that the incidence of PPM in patients
undergoing valve replacement for AR was half that of pa-
tients operated on for aortic valve stenosis, and this is likely
due to the concomitant enlargement of the aortic root in pa-
tients with AR. In our larger cohort of patients with AR,
which was previously published,15 22% of patients had
PPM. PPM is more common in cohorts mainly composed
of patients with aortic stenosis: 33% of patients having
AVR in a Canadian study7 and 62% in a study from St
Louis.16
We did not assess the effect of PPM onmortality owing to
the limited number of patients with PPM. Nevertheless, in
our larger cohort of patients with AR and AVR,15 theardiovascular Surgery c Volume 142, Number 2 e7
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FIGURE 1. The average change in LVmass from preoperative to late after
AVR for chronic AR is stratified into PPM, preoperative LVMi, and labeled
valve sizes. All data are expressed as means and error bars represent stan-
dard deviations. A, Presence or absence of PPM (indexed effective aortic
valve area<0.85 cm2/m2). There was no statistically significant difference
(P ¼ .788). B, Mild, moderate, or severely enlarged preoperative LVMi.
There was a statistically significant difference in the degree of LV mass re-
gression in these groups (P<.001). C, Grouped by valve sizes. There was
no statistically significant difference (P ¼ .439). LV, Left ventricular; AVR,
aortic valve replacement; AR, aortic valve regurgitation; PPM, patient–
prosthesis mismatch; LVMi, indexed left ventricular mass.
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overall mortality (unpublished data). Our current study dif-
fers from our previous manuscript, inasmuch as it specifi-
cally focuses on predictors of LV remodeling.
Price and coworkers14 found a trend toward less mass re-
gression in patients who had PPM after AVR for AR (differ-
ence in indexed LV mass, 30 17 g/m2; P¼ .07), althoughe8 The Journal of Thoracic and Cardiovascular Surgethey suggested that their study may have been underpow-
ered. In our analysis, the only independent predictor of ex-
tent of LV mass regression was a larger preoperative LV
mass. However, regression of hypertrophy was not com-
plete in those with the largest preoperative LVMi. Other
studies have shown that although LV mass regression oc-
curs after valve replacement for AR, it is incomplete in
most patients.17-20 In the study from Taniguchi and
colleagues20 of 82 patients with AVR for AR, regression
of LV hypertrophy was limited in patients with an LVMi
of more than 200% of normal. Taniguchi assumed that there
were no cases of PPM (effective orifice area index> 0.9
cm2/m2). In contrast, our results suggest that very large ven-
tricles can undergo reverse remodeling.
A smaller preoperative LVMi was the only independent
predictor of late normal LVMi. Other univariate associa-
tions with normal LVMi included gender (women tend to
have smaller LV mass) and higher ejection fractions. In-
dexed aortic valve area and the presence of PPM were
not related to late normal LVMi in our study. The conse-
quences of incomplete regression are unknown, but in pa-
tients with isolated hypertensive heart disease, greater LV
mass has been identified as a risk factor for mortality and
cardiovascular events, including stroke and coronary artery
disease.21-23
There are several methods to calculate prosthetic valve
‘‘size.’’24 The labeled valve size (in millimeters) refers to
the diameter of the external sewing ring in mechanical pros-
theses and the diameter of the mounting ring in stented bio-
prostheses. Using the formula of a circle, the valve area can
be calculated using these measurements. Valve manufac-
turers also provide calculated internal geometric orifice
areas that provide an in vitro measurement. In our study,
however, we used in vivo measurements of indexed aortic
valve area calculated early after operation on transthoracic
echocardiography. This provides a more realistic estimate
of the valve area. Indexed aortic valve area has been shown
to predict mismatch as well as resting and exercise postop-
erative gradients.25
A limitation of our study is that we do not have follow-up
echocardiography available on all patients at a consistent
interval. Although recommended in clinical practice, echo-
cardiograms may not be available for our review or may not
be done as suggested. Many patients are not followed up at
Mayo Clinic. Our study may also have been underpowered
to detect some differences between patient groups, as we
had only 13 patients with PPM in our cohort. Finally, this
analysis was not designed to determine whether PPM af-
fects survival, inasmuch as our inclusion criteria required
that a patient had available follow-up echocardiography.References
1. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact,
and prevention. Heart. 2006;92:1022-9.ry c August 2011
Brown et al Acquired Cardiovascular Disease
A
C
D2. Walther T, Rastan A, Falk V, Lehmann S, Garbade J, Funkat AK, et al. Patient
prosthesis mismatch affects short-and long-term outcomes after aortic valve re-
placement. Eur J Cardiothorac Surg. 2006;30:15-9.
3. Mohty D,Malouf JF, Girard SE, Schaff HV, Grill DE, Enriquez-SaranoME, et al.
Impact of prosthesis-patient mismatch on long-term survival in patients with
small St Jude Medical mechanical prostheses in the aortic position. Circulation.
2006;113:420-6.
4. Moon MR, Pasque MK, Munfakh NA, Melby SJ, Lawton JS, Moazami N, et al.
Prosthesis-patient mismatch after aortic valve replacement: impact of age and
body size on late survival. Ann Thorac Surg. 2006;81:481-8.
5. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of
prosthesis-patient mismatch on short-term mortality after aortic valve replace-
ment. Circulation. 2003;108:983-8.
6. Tasca G, Mhagna Z, Perotti S, Centurini PB, Sabatini T, Amaducci A, et al.
Impact of prosthesis-patient mismatch on cardiac events and midterm mortality
after aortic valve replacement in patients with pure aortic stenosis. Circulation.
2006;113:570-6.
7. Mohty D, Dumesnil JG, Echahidi N, Mathieu P, Dagenais F, Voisine P, et al.
Impact of prosthesis-patient mismatch on long-term survival after aortic valve re-
placement. J Am Coll Cardiol. 2009;53:39-47.
8. Blackstone EH, Cosgrove DM, Jamieson WR, Birkmeyer NJ, Lemmer JH Jr,
Miller DC, et al. Prosthesis size and long-term survival after aortic valve replace-
ment. J Thorac Cardiovasc Surg. 2003;126:783-93.
9. Howell NJ, Keogh BE, Barnet V, Bonser RS, Graham TR, Rooney SJ, et al.
Patient-prosthesis mismatch does not affect survival following aortic valve re-
placement. Eur J Cardiothorac Surg. 2006;30:10-4.
10. Koch CG, Khandwala F, Estafanous FG, Loop FD, Blackstone EH. Impact of
prosthesis-patient size on functional recovery after aortic valve replacement.
Circulation. 2005;111:3221-9.
11. Monin JL, Monchi M, Kirsch ME, Petit-Eisenmann H, Baleynaud S, Chauvel C,
et al. Low-gradient aortic stenosis: impact of prosthesis-patient mismatch on sur-
vival. Eur Heart J. 2007;28:2620-6.
12. Flameng W, Meuris B, Herijgers P, Herregods MC. Prosthesis-patient mismatch
is not clinically relevant in aortic valve replacement using the Carpentier-
Edwards Perimount valve. Ann Thorac Surg. 2006;82:530-6.
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.
American Society of Echocardiography’s Nomenclature and Standards Commit-
tee;TaskForce onChamberQuantification;AmericanCollegeofCardiologyEcho-
cardiography Committee; American Heart Association; European AssociationThe Journal of Thoracic and Cof Echocardiography, European Society of Cardiology. Recommendations for
chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
14. Price J, Chan V, Klulik A, Ressler L, Bedard P, Mesana TG, et al. Different
incidence and implications of prosthesis-patient mismatch after aortic valve
replacement for aortic insufficiency versus aortic stenosis. Available at: www.
pulsus.com/ccc2007/abs/0396.htm. Accessed on May 20, 2009.
15. Brown ML, Schaff HV, Suri RM, Li Z, Sundt TM, Dearani JA, et al. Indexed left
ventricular dimensions best predict survival after aortic valve replacement in pa-
tients with aortic valve regurgitation. Ann Thorac Surg. 2009;87:1170-5.
16. Moon MR, Lawton JS, Moazami N, Munfakh NA, Pasque MK, Damiano RJ Jr.
POINT: Prosthesis-patient mismatch does not affect survival for patients greater
than 70 years of age undergoing bioprosthetic aortic valve replacement. J Thorac
Cardiovasc Surg. 2009;137:278-83.
17. Taniguchi K, Nakano S,KawashimaY, Sakai K, Kawamoto T, Sakaki S, et al. Left
ventricular ejection performance, wall stress, and contractile state in aortic regur-
gitation before and after aortic valve replacement. Circulation. 1990;82:798-807.
18. Roman MJ, Klein L, Devereux RB, Kligfield P, Niles NW, Hochreiter C, et al.
Reversal of left ventricular dilatation, hypertrophy, and dysfunction by valve re-
placement in aortic regurgitation. Am Heart J. 1989;118:553-63.
19. Tasca G, Brunelli F, Cirillo M, DallaTombaM, Mhagna Z, Troise G, et al. Impact
of valve prosthesis-patient mismatch on left ventricular mass regression follow-
ing aortic valve replacement. Ann Thorac Surg. 2005;79:505-10.
20. Taniguchi K, Takahashi T, Toda K, Matsue H, Shudo Y, Shintani H, et al. Left
ventricular mass: impact on left ventricular contractile function and its reversibil-
ity in patients undergoing aortic valve replacement. Eur J Cardiothorac Surg.
2007;32:588-95.
21. Kahan T. The importance of left ventricular hypertrophy in human hypertension.
J Hypertens. 1998;16:S23-9.
22. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left
ventricular mass and geometry to morbidity and mortality in uncomplicated es-
sential hypertension. Ann Intern Med. 1991;114:345-52.
23. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implica-
tions of echocardiographically determined left ventricular mass in the Framing-
ham Heart Study. N Engl J Med. 1990;322:1561-6.
24. Gillinov AM, Blackstone EH, Rodriguez LL. Prosthesis-patient size: measure-
ment and clinical implications. J Thorac Cardiovasc Surg. 2004;126:313-6.
25. Pibarot P, Dumesnil JG, Cartier PC, Metras J, Lemieux MD. Patient-prosthesis
mismatch can be predicted at the time of operation. Ann Thorac Surg. 2001;
71:S265-8.ardiovascular Surgery c Volume 142, Number 2 e9
